374 related articles for article (PubMed ID: 19492872)
1. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Intermittent Vancomycin Dosage Regimens for Thai Critically Ill Population Infected by MRSA in the Era of the "MIC Creep" Phenomenon.
Setiawan E; Suwannoi L; Montakantikul P; Chindavijak B
Acta Med Indones; 2019 Jan; 51(1):10-18. PubMed ID: 31073101
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
[TBL] [Abstract][Full Text] [Related]
6. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
[TBL] [Abstract][Full Text] [Related]
7. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.
Frymoyer A; Hersh AL; Coralic Z; Benet LZ; Joseph Guglielmo B
Clin Ther; 2010 Mar; 32(3):534-42. PubMed ID: 20399990
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.
Bhongsatiern J; Stockmann C; Roberts JK; Yu T; Korgenski KE; Spigarelli MG; Desai PB; Sherwin CM
Ther Drug Monit; 2015 Dec; 37(6):756-65. PubMed ID: 26562817
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
Lewis SJ; Mueller BA
J Clin Pharmacol; 2021 Feb; 61(2):211-223. PubMed ID: 32851685
[TBL] [Abstract][Full Text] [Related]
10. Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in meticillin-resistant Staphylococcus aureus.
Mei Q; Ye Y; Zhu YL; Cheng J; Yang HF; Liu YY; Li HR; Li JB
Int J Antimicrob Agents; 2015 Jun; 45(6):652-6. PubMed ID: 25813394
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Vancomycin Dosing Regimen in Cancer Patients using Pharmacokinetic/Pharmacodynamic Modeling.
Alqahtani S; Almatrafi A; Bin Aydan N; Alqahtani M; Alzamil F; Alsultan A; Asiri Y
Pharmacotherapy; 2020 Dec; 40(12):1192-1200. PubMed ID: 33084059
[TBL] [Abstract][Full Text] [Related]
12. Initial dosage regimen of vancomycin for septic shock patients: a pharmacokinetic study and Monte Carlo simulation.
Katip Bpharm W; Jaruratanasirikul S; Pattharachayakul S; Wongpoowarak W; Jitsurong A
J Med Assoc Thai; 2014 Nov; 97(11):1209-19. PubMed ID: 25675687
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
14. Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant
Wei X; Zhao M; Xiao X
J Chemother; 2021 Dec; 33(8):547-553. PubMed ID: 34080519
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
Lodise TP; Bosso J; Kelly C; Williams PJ; Lane JR; Huang DB
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133566
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation.
Wei XC; Zhao MF; Li X; Xiao X
J Clin Pharmacol; 2020 Jun; 60(6):768-774. PubMed ID: 32080861
[TBL] [Abstract][Full Text] [Related]
17. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients.
del Mar Fernández de Gatta Garcia M; Revilla N; Calvo MV; Domínguez-Gil A; Sánchez Navarro A
Intensive Care Med; 2007 Feb; 33(2):279-85. PubMed ID: 17165021
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
Housman ST; Sutherland CA; Nicolau DP
Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
Song X; Han M
Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
